Lixisenatide (Adlyxin)

Peptide

Lixisenatide is a once-daily GLP-1 receptor agonist for type 2 diabetes. FDA-approved 2016 following ELIXA cardiovascular safety trial. GetGoal Phase 3 program (n>5,000): Significant HbA1c reductions across 13 trials. ELIXA (n=6,068): Confirmed CV safety (HR 1.02 for MACE, noninferiority P<0.001). Pronounced postprandial glucose effect - 75% reduction in glucose excursion (GetGoal-Mono). Effective add-on to basal insulin. Common side effects: nausea, vomiting (dose-dependent, resolve in 3-6 weeks).

Quick Answer

What it is

Lixisenatide is a once-daily GLP-1 receptor agonist for type 2 diabetes. FDA-approved 2016 following ELIXA cardiovascular safety trial.

Key findings

Grade A: HbA1c Reduction (Type 2 Diabetes)
Grade A: Postprandial Glucose Control (Type 2 Diabetes)
Grade A: Cardiovascular Safety (MACE) (Type 2 Diabetes)

Safety

Safe in high-risk post-ACS patients.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Lixisenatide (Adlyxin)

Quick Facts: Lixisenatide (Adlyxin)

Best Evidence:Grade A
Conditions Studied:1
Research Outcomes:13
Grade A Findings:5
Grade B Findings:4
Key Effect:Type 2 Diabetes

1 conditions · 13 outcomes

Detailed Outcomes

HbA1c Reduction

GetGoal program (13 trials, n>5,000): Consistent HbA1c reductions. ELIXA: 0.27% greater reduction vs placebo. GetGoal-L: Significant improvement when added to basal insulin. All trials met primary HbA1c endpoints.

moderate↓Improves

Postprandial Glucose Control

GetGoal-Mono: 75% reduction in postprandial glucose excursion. GetGoal-L: Placebo-corrected PPG reduction of 3.8 mmol/L (P<0.0001). Pronounced prandial effect distinguishes from other GLP-1 RAs.

large↓Improves

Cardiovascular Safety (MACE)

ELIXA (n=6,068): CV death/MI/stroke/UA hospitalization 13.4% vs 13.2% placebo (HR 1.02, noninferiority P<0.001, superiority P=0.81). No CV harm or benefit. Safe in high-risk post-ACS patients.

none

Add-on to Basal Insulin

GetGoal-L, GetGoal-L-Asia, GetGoal-Duo: Significant HbA1c and PPG improvements when added to basal insulin. Alternative to prandial insulin without weight gain. Less hypoglycemia than basal-bolus regimens.

moderate↑Improves

Gastrointestinal Side Effects

Most common: Nausea (dose-dependent), vomiting, diarrhea. Generally mild-moderate, resolve within 3-6 weeks. Similar GI profile to other GLP-1 RAs. Gradual dose titration recommended.

moderate↑Worsens